- Conditions
- Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
- Interventions
- Warfarin GenoSTAT Test
- Device
- Lead sponsor
- Iverson Genetic Diagnostics, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 3,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Major Depressive Disorder, PTSD
- Interventions
- Phlebotomy - Folate, Cheek Swab, Self-report surveys
- Genetic · Other
- Lead sponsor
- Mclean Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Pharmacogenomics and Cardiovascular Events
- Interventions
- Pharmacogenomics
- Genetic
- Lead sponsor
- Avera McKennan Hospital & University Health Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Major Depressive Disorder
- Interventions
- GeneSight Psychotropic test, Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- GeneSight Psychotropic
- Genetic
- Lead sponsor
- Assurex Health Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
- Conditions
- Perioperative/Postoperative Complications
- Interventions
- PGx Testing
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Use of Prescription Medications, Pharmacogenetic Testing
- Interventions
- Panel-based pharmacogenetic genotyping
- Diagnostic Test
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 492 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Pharmacogenomic Testing for Medication Management
- Interventions
- Not listed
- Lead sponsor
- ClinLogic LLC
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 280,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- York, Pennsylvania
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- capecitabine, celecoxib, pharmacological study, laboratory biomarker analysis, pharmacogenomic studies
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hypercholesterolemia
- Interventions
- Pharmacogenetic and polygenic risk testing, Active control
- Genetic · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Durham, North Carolina
- Conditions
- Adult Patients Who Are Receiving Oncologic Care
- Interventions
- Pharmacogenomic (PGx) results.
- Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Patients Undergoing Routine Health Care, Heart Diseases, Inflammatory Bowel Diseases, Autoimmune Disease, Inflammatory Disease, Blood Coagulation Disorders, Hepatitis C, Non-Metastatic Neoplasm
- Interventions
- Not listed
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Venous Thromboembolism, Bleeding
- Interventions
- Pharmacogenetic-based warfarin dosing, Usual care warfarin dosing
- Genetic · Other
- Lead sponsor
- Gwen McMillin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Pharmacogenetics
- Interventions
- Medication Therapy Management, Pharmacogenetic testing
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
- Interventions
- 2'-F-ara-deoxyuridine, positron emission tomography, laboratory biomarker analysis, pharmacological study, pharmacogenomic studies
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Thrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction, Ischemic Stroke
- Interventions
- Cipherome Lighthouse Pilot
- Diagnostic Test
- Lead sponsor
- Cipherome, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Edinburg, Texas
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide, veliparib, DNA methylation analysis, gene expression analysis, mutation analysis, proteomic profiling, high performance liquid chromatography, immunoenzyme technique, laboratory biomarker analysis, mass spectrometry, pharmacogenomic studies, pharmacological study, adjuvant therapy, radiation therapy
- Drug · Genetic · Other + 2 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 8 more
- Conditions
- Obsessive Compulsive Disorder, Major Depressive Disorder, Anxiety
- Interventions
- Not listed
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 8 Years to 20 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Glipizide, Metformin, Oral Glucose Tolerance Test
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,033 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2025
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Pharmacogenomic
- Interventions
- pharmacogenomic
- Genetic
- Lead sponsor
- Data Collection Analysis Business Management
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Land O' Lakes, Florida
- Conditions
- Chronic Pain
- Interventions
- Pharmacogenetic testing, Clinical decisions support
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,048 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Indianapolis, Indiana + 3 more
- Conditions
- Pharmacogenetic Testing
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- dabrafenib, pazopanib hydrochloride, Correlative studies
- Drug · Other
- Lead sponsor
- Manisha Shah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Houston, Texas
- Conditions
- HIV/AIDS, Nicotine Dependence
- Interventions
- Varenicline, Nicotine patch, Standard treatment, Standard treatment + Managed Problem Solving (MAPS) adherence intervention
- Drug · Behavioral
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Philadelphia, Pennsylvania